A role for BRCA1 in sporadic breast cancer by Fraser, J A et al.
A role for BRCA1 in sporadic breast cancer
JA Fraser
1,4, JR Reeves
1,4, PD Stanton
1, DM Black
2, JJ Going
3, TG Cooke
1 and JMS Bartlett*
,1
1University Department of Surgery, Glasgow Royal Infirmary, 10 Alexandra Parade, Glasgow G31 2ER, UK;
2Beatson Institute for Cancer Research,
Switchback Road, Bearsden, Glasgow, Scotland, UK;
3Department of Pathology, Glasgow Royal Infirmary, 10 Alexandra Parade, Glasgow G31 2ER, UK
To test the hypothesis that altered expression of BRCA1 protein may play an important role in sporadic breast cancer development,
50 randomly selected primary breast cancers (frozen sections, 5 years’ median follow-up) were immunolabelled with two monoclonal
BRCA1 antibodies (MS110 and MS13). MS110 labelling was exclusively nuclear showing no relation to outcome or tumour
pathology. Western blotting demonstrated crossreactivity, suggesting antibody nonspecificity. MS13 labelling was predominantly
cytoplasmic. Intense labelling predicted decreased overall survival (P¼0.012), disease-free survival (P¼0.029), oestrogen receptor
negativity (P¼0.0004) and c-erbB-2 overexpression (P¼0.006). Western blotting detected a 110kDa molecule consistent with
BRCA1 D11b splice variant. BRCA1 protein is postulated to function as a tumour suppressor. We demonstrate cytoplasmic
localisation in sporadic breast cancer suggesting excess D11b splice variant production, reduced production of full-length BRCA1 and
thus postulate reduced tumour suppressor activity. BRCA1 protein appears to have a significant role in both sporadic and hereditary
breast cancers.
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Approximately 90% of extensive breast and/or ovarian cancer
families have loss of function germline mutations in the tumour
suppressor genes BRCA1 or BRCA2 (17q21 and 13q12–q13,
respectively). Germline mutations in BRCA1 account for about
3% of all breast cancers, with a further 2% resulting from
mutations in BRCA2. Breast cancer patients with mutated BRCA1
frequently demonstrate loss of the corresponding wild-type allele
(Cornelis et al, 1995). Fibroblasts expressing BRCA1 antisense
RNA, with correspondingly low levels of endogenous BRCA1
protein, display accelerated growth and higher tumorigenicity in
nude mice than their control counterparts (Rao et al, 1996).
Retroviral transfection of wild-type BRCA1 inhibits growth of
breast and ovarian cancer cells in vitro but not those derived from
colon or lung (Holt et al, 1996). Since these cell lines are raised
from sporadic cancers, these data provide strong support for a role
for BRCA1 in sporadic breast cancer. Mutant BRCA1 transfection
does not inhibit breast cancer cell growth; ovarian cancer cell
growth is unaffected by 50 but inhibited by 30 BRCA1 mutations
(Holt et al, 1996). In nude mice, MCF-7 breast cancer tumour
growth is inhibited by transfection with wild-type but not mutant
BRCA1 (Holt et al, 1996). Thus, BRCA1 clearly has an important
role in the control of breast neoplasias of sporadic origin.
Wild-type BRCA1 binds to a number of cellular proteins
involved in cell cycle regulation including the DNA repair protein
Rad51, the tumour suppressor p53, RNA polymerase II holo-
enzyme, RNA helicase A, CtBP-interacting protein, c-myc, BARD1,
BRCA2 protein, etc. BRCA1 is postulated to mediate the
involvement of these proteins in DNA repair, transcriptional
transactivation and cell cycle control by acting as a converging
vehicle for protein association (Scully et al, 1997a; Anderson et al,
1998; Yu et al, 1998; IrmingerFinger et al, 1999). By affecting
BRCA1 protein tertiary structure, BRCA1 mutations may thus
disrupt complex associations precipitating dysregulation of
cellular functions and eventual progression to malignancy.
BRCA1 germline mutations have been described in only a
handful of sporadic breast cancer cases (Futreal et al, 1994; Garcia-
Patino et al, 1998) where they are likely to represent de novo
mutations. No somatic BRCA1 gene mutations have been identified
without simultaneous germline mutations, unlike ovarian cancer,
where single somatic BRCA1-truncating mutations have been
identified (Merajver et al, 1995). BRCA1 protein products may
however have an important role in the development of sporadic
breast cancers as shown by transfection studies. Increasing
evidence exists that abnormal BRCA1 expression plays a key role
in nonhereditary cases, with messenger RNA levels being higher
within normal breast epithelium and noncomedo in situ breast
disease than in cases of sporadic invasive cancer (Thompson et al,
1995). Methylation of cytosine residues is a well-recognised
explanation for reduced gene expression when no gene mutations
or LOH is present (methylation silencing). Indeed, aberrant
methylation of the BRCA1 CpG island promoter at the 50 end of
the BRCA1 gene has been described and is associated with
significantly reduced levels of BRCA1 mRNA (Rice et al, 1998),
supporting this hypothesis.
With the recent development of BRCA1-specific antibodies
(Chen et al, 1995; Scully et al, 1996), immunohistochemical
analysis of tumours is now possible. We have studied 50 randomly
selected primary breast cancers by immunohistochemistry using
MS110 and MS13 monoclonal antibodies to investigate the relation
of BRCA1 expression to pathological, biological and survival
parameters.
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Patients
Frozen tumour tissue was obtained from 50 randomly selected
primary operable breast cancer cases treated in Glasgow Royal
Infirmary from 1984 to 1993. Ages ranged from 40 to 77 years
(mean age 60.85) at the time of surgery. Pathology confirmed 47
ductal, two medullary and one lobular carcinoma. Patients were
followed up in a dedicated breast clinic (median follow-up 5 years).
Follow-up was dated to the last documented clinic visit with all
recurrences being confirmed by clinical investigation and, where
appropriate, pathology. Conventional pathological data were
collected (Table 1). Mortality data were cross-referenced with the
regional cancer registry. Normal breast tissue was obtained from
seven patients undergoing reduction mammoplasty for use as a
negative control.
Tissue culture
MCF-7, SKOV-3, ZR75-1 and BT20 cells were grown in RPMI and
MDA-MB-361, MDA-MB-453, SKBR3 and BT474 cells in DMEM,
both supplemented with 10% foetal bovine serum (cell lines
available from the American Type Cell Culture Collection). Cells
were cultured in a 95% air, 5% CO2 humidified atmosphere at
371C. Cells were grown to near confluence in 175cm
2 flasks,
harvested by scraping and centrifugation at 100g, and resuspended
in 10ml of PBS (10mM sodium phosphate, 140mM sodium
chloride pH 7.4). Cells were pelleted at 300g and cell pellets were
stored in liquid nitrogen prior to immunohistochemistry.
Cell fractionation and lysate preparation
Total protein lysates were prepared from 70–100% confluent cells.
Cells were recovered by incubation with 0.125% wv
 1 trypsin,
resuspended in RPMI supplemented with 10% FCS, and washed
with PBS prior to lysis in modified RIPA buffer (PBS containing
1% Triton X-100, 0.1% SDS and a cocktail of protease inhibitors:
100mgml
 1 phenylmethylsulphonyl fluoride (PMSF), 10mgml
 1
leupeptin, 10mgml
 1 pepstatin, 20mgml
 1 aprotinin and 10mmol
benzamidine). Lysates were passed through a 28-gauge needle,
rotated for 20min at 41C, and then centrifuged at 15000g for
20min to precipitate insoluble cellular debris. Protein yield was
estimated spectrophotometrically at 595nm using the Bradford
method (Bradford, 1976).
For cell fractionation, 8–12 175cm
2 flasks were collected as
above, and washed with PBS. Cells were resuspended in 1.5–2ml
hypotonic buffer (30mM Hepes, pH 7.5, 5mM KCl, 1mM MgCl2)
and protease inhibitor cocktail as above. After a 30-min incubation
on ice, cells were homogenised with a tight-fitting dounce
homogeniser and lysis was monitored by microscopy. An equal
volume of NP-40 lysis buffer (10mM Tris, pH 7.4, 250mM sucrose,
1.0mM MgCl2, 0.1% NP-40) was added to complete lysis. Nuclei
were collected by centrifugation at 3000g, washed twice in NP-40
lysis buffer, and then lysed in modified RIPA buffer. Both nuclear
and cytoplasmic fractions were centrifuged at 15000g to
precipitate insoluble cellular debris.
Tumour protein extraction for immunoblotting
Tumours were selected from the highest and lowest MS13 scoring
groups. Tumour blocks were maintained at  201C or lower.
Dismembranation was achieved by pulsing for 8 1min at 2000
cyclesmin
 1 (Mikro Dismembrator, Braun Biotech International).
Chilled modified RIPA buffer (500ml) was added and the mixture
pulsed for a further 2min. The mixture was then mixed for 30min
at 41C before being centrifuged at 15000g to pellet insoluble
cellular debris. Protein yield was estimated as previously
described. Supernatant was collected and stored frozen as whole-
cell lysate.
Immunoblotting analysis
Immunoblotting was performed on breast carcinoma cell lines
MCF-7 and SKOV-3 and tumour lysates. In total, 100mg of each
cellular protein lysate (whole cell, nuclear or cytoplasmic) was
denatured by boiling for 10min in Laemmli buffer and then run on
6% SDS–polyacrylamide gel. Proteins were transferred by
electrophoresis at 15V for 120–180min to Bio-rad Sequi-Blot
PVDF membrane using a Biorad semidry blotter. The membrane
was blocked in 5% nonfat milk, 10% sheep serum in Tris buffered
saline (TBS: 0.01 M Tris/HCl pH 7.4, 0.15 M NaCl) supplemented
with 0.05% Tween 20 (TTBS-milk) overnight at 41C. The
membrane was incubated for 2h at room temperature with
primary antibody in TTBS-milk (antibody concentration of
2mgml
 1 in the case of both MS13 and MS110). Washes were
performed in TTBS. Secondary antibody was peroxidase- labelled,
affinity purified sheep anti-mouse IgG (Sigma Chemical Company)
at a dilution of 1:5000 applied for 40min. The peroxidase signal
was developed with ECL as per the manufacturer’s directions
(Amersham International, Amersham, UK).
Immunohistochemistry
Frozen section immunohistochemistry was performed as pre-
viously reported (Reeves et al, 1996). Briefly, 5mm acetone-fixed
cryostat sections of tumour, normal breast tissue or cell line pellets
were labelled with monoclonal anti-BRCA1 antibodies MS110 and
MS13 (Scully et al, 1996) (BRCA1 Ab1 and Ab2, respectively,
supplied by Oncogene Research Products, Calbiochem Novabio-
chem (UK) Ltd, Nottingham, UK). All steps were performed at
room temperature in a humidified cabinet. Endogenous biotin was
suppressed prior to immunohistochemical labelling, and non-
specific binding was further blocked by preincubating the sections
with 25% of both rabbit and human serum in PBS. Sections were
incubated with primary antibody for 2h (antibody concentration
of 1mgml
 1 in both cases). Antigen was detected with biotinylated
Table 1 Relation of MS110 and MS13 immunostaining to pathology (w
2)
[MS110] [MS13]
N( % ) v
2 P v
2 P
Nodal status
Negative 21 (42) 0.246 0.62 0.027 0.87
Positive 28 (56)
Size (mm)
T1 (o21) 16 (33)
T2 (21–50) 27 (56) 0.404 0.82 0.783 0.68
T3 (450) 5 (10)
Grade
1 6 (12)
2 21 (42) 0.679 0.71 4.464 0.11
3 23 (46)
Oestrogen receptor
Negative 22 (48%) 2.14 0.14 12.54 0.0004
Positive 24 (52%)
NPI
1( o3.4) 7 (14%) 0.860 0.651 0.598 0.742
2 (3.41–5.4) 28 (56%)
3( 45.4) 12 (24%)
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applied for 30min at a dilution of 1:400 prior to using the
streptavidin–biotin–peroxidase complex detection system (Dako,
High Wycombe, UK) according to the manufacturer’s instructions.
In all, 10% each of human and rabbit serum were included in the
primary and secondary antibody diluent. The peroxidase signal
was developed with a 10-min exposure to 0.07% nickel chloride,
0.025% diaminobenzidine tetra hydrochloride and 0.01% hydrogen
peroxide producing a black precipitate. The nuclei were counter-
stained with safranin before dehydration and mounting. Negative
controls were performed on parallel sections by using isotype-
matched nonimmune immunoglobulin in place of the primary
antibody.
To confirm the specificity of the MS13 and MS110 antibody, the
epitope to which they had been raised was synthesised. This
protein fragment competitively inhibited antibody binding in
tissues known to give positively labelled results.
Immunohistochemical scoring
Two different methods of immunohistochemical scoring were
utilised because of the differences in staining patterns. MS110
staining was nuclear and so a conventional scoring method was
employed, estimating the percentage of labelled tumour cell nuclei.
MS13 staining was however cytoplasmic and thus a histoscore was
calculated from the sum of (1 % weakly positive)+(2 %
moderately positive)+(3 % strongly positive) with a maximum
of 300. The mean of the two observers’ scores was used for
analysis.
Statistics
BRCA1 scores for each antibody were treated as binary variables
(above or below the median score). Tumours with higher than
median and lower than median MS110 or MS13 scores were
assessed in relation to the following biological variables: nodal
status, Bloom and Richardson tumour grade, oestrogen receptor
status and tumour size using w
2 analysis and with the continuous
variable age using the Mann–Whitney test. Life table analysis of
overall and disease-free survival was performed using Kaplan–
Meier estimates and log-rank tests. Spearman’s rank correlation
was used for direct comparison of the scores with the two
antibodies on the tumour samples.
Analysis of agreement for each set of measurements was
conducted using the methods of Bland and Altman (1986, 1999).
The mean difference between measurements was obtained and
95% confidence intervals for the mean calculated. If these
confidence intervals span zero, it is judged that there is no
systematic bias measurements in between observers.
RESULTS
MS110 immunohistochemistry
In histologically normal epithelium from breast reduction speci-
mens MS110 revealed nuclear labelling in approximately 1–5% of
epithelial cells (Figure 1A). The same staining pattern was present
in cell lines (nuclear labelling range 2–50%) (Figure 1D and
Table 2) and in sporadic breast tumour specimens (nuclear
labelling ranging p1–60%) (Figures 1G, J). No labelling was
present in the parallel control sections (Figures 1C, F, I, L). Of the
two independent observers’ (JRR and JJG) scores (Figure 2A),
JRR’s estimations of the proportion of MS110-labelled nuclei
ranged from 1 to 70% with a median of 10%, whereas JJG’s scores
ranged from 0 to 50% with a median of 5%. For statistical analysis,
the mean of both observers’ scores was calculated and categorised
on a binary basis on either side of the median.
Comparison of MS110 scores between observers produced a
mean difference of 5.30. The 95% confidence intervals for the mean
do not include zero (2.18–8.42), reflecting a small systematic bias
in the scoring (P¼0.001). Nonetheless, the Pearson correlation
coefficient (0.72, P¼0.0001) and the 95% limits of agreement span
a sufficiently small range ( 16.68 to 27.28) to enable the two
observers’ scores to be deemed comparable. Similarly, comparison
of MS13 histoscores produced a mean difference of  13.52. The
95% confidence intervals for the mean are  22.65 to  4.39. Once
again the confidence intervals do not include zero, reflecting a
systematic bias in the histoscoring. The Pearson correlation
coefficient is 0.922 (P¼0.0001) and although the 95% limits of
agreement ( 77.75 to 50.71) are broad, given the histoscore range
of 0–300, they can be considered to demonstrate acceptable
interobserver agreement. Again the mean of the two observers’
scores was used for analysis.
MS13 immunohistochemistry
MS13 antibody immunostaining pattern was strong, cytoplasmic
and always confined to the ductal and terminal ductal lobular unit
epithelial cells in histologically normal breast tissue (Figure 1B).
Within all cell lines (Figure 1E and Table 2) and sporadic breast
tumour samples (Figures 1H, K), the signal was cytoplasmic with
mean histoscores ranging from 0 to 140 and 0 to 257.5,
respectively. Parallel control sections of normal and malignant
breast samples, and cell lines demonstrated no staining (Figures
1C, F, I, L). Again the mean of the two observers’ scores was used
for analysis (Figure 2B). JRR’s histoscores ranged from 0 to 270
with a median of 50, and JJG’s ranged from 0 to 260 with a median
of 66. As above, the mean of the two observers’ scores was
calculated and categorised on a binary basis on either side of the
median.
BRCA1 expression in relation to tumour pathology
Oestrogen receptor positive tumours were significantly more likely
to have lower MS13 histoscores (mean histoscore 87.2) than their
oestrogen receptor negative counterparts (mean histoscore 136.8)
(P¼0.0004). No significant relation (PX0.05) was demonstrated
between the proportion of MS110 positive nuclei or MS13
histoscore and patient age, nodal status, tumour size, tumour
grade or the Nottingham Prognostic Index (Galea et al, 1992),
which combines the prognostic information given by nodal status,
tumour size and tumour grade (Table 1).
A relation was sought between MS110 and MS13 staining
patterns and c-erbB-2 and epidermal growth factor receptor data
previously published by this group (Reeves et al, 1996; Robertson
et al, 1996). A strong relation was evident between intensity of
MS13 labelling and increased c-erbB-2 expression (P¼0.006). This
was confirmed by fluorescent in situ hybridisation (FISH) where
high MS13 scorers correlated with the FISH positive expressors
(P¼0.03) (in-house data) (Bartlett et al, 2001). No relation was
demonstrated between epidermal growth factor receptor (EGFR)
and either antibody score. Direct comparison of paired MS13 and
MS110 histoscores was performed and demonstrated no relation.
BRCA1 expression in relation to outcome
Univariate survival analysis was carried out for both sets of data
using Kaplan–Meier estimates and log-rank tests. MS110 im-
munostaining did not relate to disease-free (P¼0.62) or overall
survival (P¼0.62) in this group. However, high MS13 histoscores
were associated significantly with both a shorter overall survival
(P¼0.012; Figure 3A) and disease-free interval (P¼0.029;
Figure 3B).
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Differing concentrations of the 304 amino-acid protein fragment
were used. Staining remained present at lower concentrations
(p53mgml
 1), but disappeared as epitope concentrations were
increased (absent at X70mgml
 1).
Western blotting analysis
Western blots were carried out to ensure that both antibodies used
for immunohistochemistry were sensitive and specific for BRCA1.
MS110 detected both 220 and 110kDa bands in the whole cell
and the nuclear fractions of both cell lines tested as well as
A B C
D E F
G H I
J K L
Figure 1 (A) Normal breast epithelium labelled with MS110 demonstrating nuclear staining of approximately 1–5% of tumour nuclei; (B) parallel section
stained with MS13 demonstrating strong cytoplasmic staining of the ductal and terminal ductal lobular unit; (C) parallel control section; (D) SKBR-3 cell line
section labelled with MS110 showing nuclear labelling; (E) a parallel section stained with MS13 demonstrating cytoplasmic staining (histoscore 140); (F)
parallel control section; (G) sporadic breast cancer section labelled with MS110 (estimated 30% labelling of the tumour nuclei); (H) parallel section stained
with MS13 (mean histoscore 80); (I) parallel control section; (J) sporadic breast cancer section labelled with MS110 (estimated 5% labelling of the tumour
nuclei); (K) parallel section stained with MS13 (mean histoscore 270); (L) parallel control section. Control sections were labelled with isotype-matched
nonimmune immunoglobulin in place of the primary antibody. Bars¼20mM.
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length and splice variant of BRCA1, MS110 crossreacts with a
number of other proteins (Figure 4).
MS13 detected a 110kDa band in the whole cell and cytoplasmic
fractions of the cell lines tested, with a faint shadow also in the
nuclear fraction, consistent with it detecting the D11b splice
variant (Figure 4). A faint 220kDa band could also be detected in
whole-cell lysates.
Low- and high-scoring tumours from the MS13 immunostained
group were selected and protein was extracted for Western
blotting. This confirmed MS13 to label a 110kDa molecule in the
tumour setting, consistent with the cell line Western blot findings
(Figure 5). MS110 detected numerous bands ranging from 286 to
54kDa, an identical picture to that seen with the cell lines.
DISCUSSION
The BRCA1 gene and its protein products have been the subject of
intensive investigation over recent years because of their proven
role in hereditary and putative role in sporadic human breast and
ovarian cancer. Controversy concerning the subcellular localisa-
tion of the BRCA1 protein has abounded, with it being reported as
nuclear (Scully et al, 1996), nuclear in normal but cytoplasmic in
breast and ovarian carcinoma cells (Chen et al, 1995), membrane
associated on the cytoplasmic aspect of nuclear invaginations
(Coene et al, 1997), or a secreted growth inhibitor (Holt et al, 1996;
Jensen et al, 1996). This debate has been fuelled by concerns
regarding the specificity of the monoclonal antibodies available for
BRCA1 detection (Wilson et al, 1996; Thakur et al, 1997).
MS110 and MS13 are monoclonal antibodies raised to the N-
terminal 304 amino acids of BRCA1 (Scully et al, 1996) supposedly
specific to BRCA1. Data presented here demonstrate different
staining patterns for these two antibodies in frozen breast cancer
sections, suggesting that these antibodies recognise distinct
protein species or isoforms of the same protein. Staining with
both antibodies was successfully competitively inhibited using the
304 amino-acid N-terminus to which the antibodies had been
raised, confirming the ability of MS110 and MS13 to detect the
BRCA1 N-terminus but not ruling out crossreactivity with
confounding proteins.
Western blot analysis, following full optimisation of the
conditions, demonstrated MS13 to be specific for a 110kDa
protein consistent with the previously reported D11b splice variant
of BRCA1 (Wilson et al, 1997), with occasionally a 220kDa
molecule faintly demonstrable in cell extracts. No crossreactivity
Table 2 Immunohistochemical data for cell lines
Cell line/tumour MS110 % +ve nuclei MS13 histoscore
MDA-MB-361 25 10
MDA-MB-453 2 125
ZR75-1 5 0
MCF7 15 0
SKBR3 50 140
BT20 20 80
BT474 40 25
SKOV-3 40 5
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Figure 2 Frequency histograms demonstrating the distribution of (A)
MS110 labelling and (B) MS13 labelling in 50 randomly selected sporadic
breast cancers.
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Figure 3 (A) Survival curve analysis (from all causes) according to low
and high immunohistochemical labelling with the MS13 antibody and (B)
disease-free survival curve analysis (local and distant recurrence). Arrow-
heads indicate censored events (Kaplan–Meier estimates and log-rank
tests).
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swith other protein species was observed. Furthermore, the 304
amino-acid BRCA1 N-terminus was readily identified on Western
blot using MS13. In contrast, while MS110 also detected a 110 and
a 220kDa product, numerous other proteins were also detected,
suggesting significant crossreactivity with non-BRCA1 protein
species. MS110 did, however, also readily identify the 304 amino-
acid N-terminus of the BRCA1 protein in Western blot analysis.
These data support the conclusion that MS13 is specific for BRCA1
detecting the BRCA1 D11b splice variant in a highly specific
manner, while MS110 lacks specificity in Western analysis. In the
light of these findings, staining with the Ab1 antibody cannot be
clearly linked with BRCA1 expression.
Previous studies using anti-BRCA1 antibodies have described
crossreactivity with various different molecules (Wilson et al,
1996). In this study, EGFR immunohistochemistry was performed
in parallel with MS13 and MS110 immunohistochemistry. EGFR
staining patterns were entirely distinct from those observed with
either MS110 or MS13. Furthermore, although an association was
observed between the intensity of MS13 immunostaining and high
c-erbB-2 expression, the staining pattern for c-erbB-2 was also
distinct from that of MS13. Additionally, two tumours with
previously demonstrated c-erbB-2 gene amplification and very
high c-erbB-2 protein expression (Reeves et al, 1996; Robertson
et al, 1996) were present in the patient cohort and were entirely
negative by MS13 immunohistochemistry. These data suggest that
MS13 does not crossreact with these members of the type one
growth factor receptor family.
The D11b splice variant lacks the majority of exon 11 (amino
acids 263–1365) and the resultant 110kDa protein lacks the
nuclear localisation signal. This protein is thought to accumulate
in the cytoplasm (Thakur et al, 1997; Wilson et al, 1997). Synthesis
of full-length BRCA1 protein is rapidly followed by translocation
to the cell nucleus. Despite Western analysis of MS110 demon-
strating crossreactivity with a number of protein species, both
nuclear and cytoplasmic in localisation, IHC staining with MS110
is almost exclusively nuclear. Although crossreactivity with a non-
BRCA1 nuclear located protein in IHC cannot be excluded. It is
probable that the MS110 antibody demonstrates stronger affinity
for the full-length protein in its native, full-length form.
Cell fractionation studies described here confirmed the 110kDa
protein species detected by MS13 to be predominantly localised in
the cytoplasmic cell fractions, thus confirming the immunohisto-
chemical results. The faint presence of the 110kDa molecule in the
nuclear fraction is likely to represent contamination of the nuclear
fraction at the time of preparation. Alternatively, a further as yet
unrecognised nuclear localisation signal could exist, allowing some
translocation of the D11b splice variant to the nucleus. Further
studies on the subcellular localisation of the D11b splice variant
would be required to address this.
In this study, immunohistochemistry and Western blotting
results for MS13 are concordant. The MS110 antibody is clearly
nonspecific, and results should not be extrapolated to BRCA1.
MS13 staining is also consistent with the lack of a nuclear
translocation signal. Hence, three strands of evidence confirm our
results to be correct and reproducible under different fixation
conditions. Previous work has suggested that MS13 staining is
predominantly nuclear and represents the full-length protein
(Wilson et al, 1999). However, recent immunoblotting data from
the same group (http://www.med.ucla.edu/ora/manuscripts.htm)
showed MS13 to detect the D11b splice variant in the cytoplasm as
well as the full-length BRCA1 species in the nucleus. Our failure to
detect nuclear MS13 staining may represent lower concentrations
of this protein than levels of splice variant detected in the
cytoplasm.
A significant relation was demonstrated between MS13 labelling
and overall survival (P¼0.012) and disease-free survival
(P¼0.029), with increasing intensity of staining indicating
worsening outcome in both situations (Figure 3A, B). Intense
MS13 staining was also significantly associated with high c-erbB-2
expression (P¼0.006) and oestrogen receptor negativity
(P¼0.0004), both indicators of a poorer prognosis. Familial breast
carcinomas with germline mutations of BRCA1 are frequently
associated with absence of c-erbB-2 expression (Lakhani et al,
2002). However, care should be taken in extrapolating findings
from cases with mutational alterations to BRCA1 to those with
potentially physiologically relevant variations in expression of
different isoforms. Our study suggests that sporadic breast cancers
with overproduction of the D11b splice variant are commonly
associated with overexpression of c-erbB-2. Oestrogen and
progesterone have both previously been reported to induce BRCA1
expression in breast cancer cell lines containing these nuclear
hormone receptors (Gudas et al, 1995). Initially thought to be a
direct response to oestrogen stimulation, increased BRCA1
expression has now been demonstrated to be a response to the
increased DNA synthesis initiated by oestrogen stimulation (Marks
et al, 1997). The function of nuclear BRCA1 as a cell cycle
checkpoint regulator has, however, been suggested to be a
response to DNA aberrations requiring repair rather than a direct
response to DNA synthesis itself (Marquis et al, 1995; Scully et al,
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Figure 4 SKOV-3 whole, cytoplasmic and nuclear fractions (100mg
aliquots lanes 1 – 3, and 200mg aliquots lanes 4–6) probed with (A)
MS110 demonstrating multiple bands of various molecular weights and (B)
MS13 demonstrating one band of 110kDa in the whole cell and
cytoplasmic fractions and faintly in the nuclear fraction.
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Figure 5 Sporadic breast cancer tumours (tumour A lanes 1 and 2,
tumour B lanes 3 and 4). Whole-cell protein lysate (100 and 200mg
aliquots) probed with MS13 demonstrating the presence of one detected
molecule of 110kDa.
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receptor c-erbB-2 induces BRCA1 transcription by a similar
pathway. This would suggest that the increase in cell proliferation
with associated genetic mutations common to all tumours should
cause an increase in BRCA1 transcription and translation. This
study would suggest that in sporadic breast cancer cases the
overproduced BRCA1 species is the D11b splice variant.
No function has as yet been ascribed to the cytoplasmically
located D11b splice variant; however, the fact that analyses have
shown that elimination of exon 11 by differential splicing also
occurs in the mouse (Hakem et al, 1996) is strong evidence that
this message may encode a protein of physiological importance. In
vivo work has confirmed the D11b splice variant to be transcribed
at physiologically significant levels (Gudas et al, 1995, 1996).
Significant data exist suggesting that the D11b splice variant is
functionally distinct from full-length BRCA1 in several respects. (i)
As a result of splice elimination of the NLS encoded in exon 11b,
the D11b protein cannot autonomously translocate to the nucleus.
(ii) The BRCA1 D11b splice variant does not exhibit the cell
toxicity apparent with overexpression of the full-length protein in
transiently transfected cells. (iii) The D11b splice variant mRNA
has been reported to be differentially reduced or absent in breast
and ovarian tumour cell lines relative to exon 11b and transcripts
with and without exons 9 and 10 (Wilson et al, 1997). All would
support a function for the BRCA1 D11b splice variant distinct to
that of full-length BRCA1.
Altering the intracellular localisation of the BRCA1 species may
act as an important physiological regulatory mechanism. In the
normal setting, DNA synthesis and genetic mutations are relatively
low. A correspondingly low level of full-length BRCA1 compared to
splice variant would thus be expected as was found in normal
breast epithelium in our data. Similarly, an increase in full-length
BRCA1 production could be expected to deal with the increased
number of genetic mutations occurring in the malignant setting. In
sporadic breast cancer however, it appears that an excess of
BRCA1 D11b splice variant is produced, perhaps signifying the
malfunction of this physiological control mechanism.
No significant correlation was observed with any of the other
biological or pathological markers studied (nodal status, tumour size,
tumour grade), suggesting that increased levels of D11b splice variant
are an independent marker of poor prognosis. This is currently
under investigation in a larger cohort of patients in our laboratory.
This study demonstrates that MS13 labelling is associated
significantly with poor prognosis. MS13 appears to preferentially
label the D11b splice variant of BRCA1. It would therefore appear
that presence of the D11b splice variant is a strong negative
prognostic marker in sporadic breast cancer. These data demon-
strate the importance of the BRCA1 regulatory system in sporadic
tumours. No significant association between MS13 histoscore and
the Nottingham Prognostic Index (Galea et al, 1992) is seen in this
series. Although performed in a limited series of cases, we are able
to hypothesise from these data that alterations to BRCA1 function,
other than inherited mutational changes, may play a significant
role in the pathophysiology of breast cancer. We are currently
testing this hypothesis in a wider patient cohort to evaluate the
potential of MS13 immunohistochemistry as an independent
prognostic marker of patient outcome. Should this research
confirm our preliminary data, evidence will be provided that
BRCA1 is a powerful mediator of sporadic breast cancer
aggressiveness.
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